Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 462.50
Bid: 455.00
Ask: 470.00
Change: 0.00 (0.00%)
Spread: 15.00 (3.297%)
Open: 462.50
High: 462.50
Low: 462.50
Prev. Close: 462.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Journal of Ultrasound in Medicine & Biology

27 Feb 2017 07:00

RNS Number : 8492X
Tristel PLC
27 February 2017
 

 

Tristel plc

("Tristel" or the "Company")

 

Tristel's Wipes and foam disinfectants included in Journal of Ultrasound in Medicine & Biology

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces that the World Federation for Ultrasound in Medicine & Biology has provided guidance to healthcare organisations worldwide regarding the safe and effective cleaning and disinfection of transvaginal and transrectal ultrasound probes.

 

The Technical Note identifies various high-level disinfectants that are recommended by ultrasound manufacturers and comments that Tristel's chlorine dioxide is being used extensively in the United Kingdom and Australia. Both the Trio Wipes System and the Duo Foam product are named. Tristel is pursuing a regulatory approval from the United States Food and Drug Administration (FDA) for the Duo Foam.

 

The Technical Note concludes that disinfection of the ultrasound probe is mandatory. However, in many countries probes are not disinfected even though the probe is used in gynaecological procedures where there is a proven high risk of contamination of the instrument by pathogens such as human immunodeficiency virus (HIV) and human papillomavirus (HPV). HPV is proven to be the main causal agent for cervical cancer. In addition, specific concerns include gonorrhoea and syphilis for vaginal probes and Clostridium difficile for transrectal probes.

 

The study has been published as a Technical Note in the Journal of Ultrasound in Medicine & Biology

[Abramovich, J. S., Evans, D. H., Fowlkes, J. B., Marsal, K., terHaar, G. 'Guidelines for Cleaning Transvaginal Ultrasound Transducers Between Patients', (2017). DOI: 10.1016/j.ultrasmedbio.2017.01.002].

 

Paul Swinney, CEO of Tristel plc, comments: "Ultrasound scans in women's health are one of the world's most commonplace diagnostic procedures. It is astounding that so many of these procedures are undertaken without the instrument being properly disinfected between patients. Our Trio and Duo products are two of very few disinfectant products that are designed specifically for women's health. Guidance such as this from the World Federation can only encourage patients to demand that the instrument being used on them is safe because it has been properly disinfected."

 

For further information please contact:

 

Tristel plc

www.tristel.com

Paul Swinney, Chief Executive 

Tel: 01638 721 500

Liz Dixon, Finance Director

 

 

 

finnCap

 

Geoff Nash / Giles Rolls, Corporate Finance

Tel: 020 7220 0500

Alice Lane, Corporate Broking

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRALLFLDFVISFID
Date   Source Headline
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.